Jefferies Group
ESPR icon

Jefferies Group’s Esperion Therapeutics ESPR Stock Holding History

Jefferies Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,700
Closed -$936K – 2208
2019
Q4 		$936K Hold
15,700
– – 0.01% 1500
2019
Q3 		$576K Hold
15,700
– – ﹤0.01% 1807
2019
Q2 		$730K Buy
+15,700
New +$737K 0.01% 1464
2018
Q4 		– Sell
-26,600
Closed -$1.18M – 2255
2018
Q3 		$1.18M Buy
+26,600
New +$1.22M 0.01% 1247
2015
Q3 		– Sell
-242,800
Closed -$19.9M – 2497
2015
Q2 		$19.9M Buy
242,800
+205,600
+553% +$20.1M 0.1% 165
2015
Q1 		$3.44M Buy
+37,200
New +$2.4M 0.02% 558

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Group's ESPR Position: Q2 2021 in Review

Jefferies Group sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 9,008 shares — an estimated $253K sold.

Jefferies Group first reported a position in ESPR in Q4 2014 and held it in 5 quarters. The position peaked at $714K in Q3 2019. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Jefferies Group reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 9,008 Esperion Therapeutics shares in Q2 2021, an estimated $253K.
  • Jefferies Group first reported a position in Esperion Therapeutics in Q4 2014 and held it in 5 quarters.
  • Jefferies Group's Esperion Therapeutics position peaked at $714K in Q3 2019.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.